1. Home
  2. ETV vs NUVB Comparison

ETV vs NUVB Comparison

Compare ETV & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

N/A

Current Price

$15.19

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

N/A

Current Price

$4.96

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ETV
NUVB
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.1B
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
ETV
NUVB
Price
$15.19
$4.96
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $13.00
AVG Volume (30 Days)
188.5K
★ 5.1M
Earning Date
01-01-0001
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 71.56
EPS
★ N/A
N/A
Revenue
N/A
★ $62,902,000.00
Revenue This Year
N/A
$211.79
Revenue Next Year
N/A
$45.15
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 698.96
52 Week Low
$13.13
$3.36
52 Week High
$15.49
$9.75

Technical Indicators

Market Signals
Indicator
ETV
NUVB
Relative Strength Index (RSI) 53.60 29.49
Support Level $14.26 $4.10
Resistance Level $15.40 $5.16
Average True Range (ATR) 0.21 0.24
MACD -0.01 -0.06
Stochastic Oscillator 61.51 20.80

Price Performance

Historical Comparison
ETV
NUVB

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: